78Q Stock Overview
A biotechnology company, develops drugs for oncology and chronic inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Philogen S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €19.80 |
| 52 Week High | €22.00 |
| 52 Week Low | €16.25 |
| Beta | 0.19 |
| 11 Month Change | 1.80% |
| 3 Month Change | -6.60% |
| 1 Year Change | 10.92% |
| 33 Year Change | 47.98% |
| 5 Year Change | n/a |
| Change since IPO | 34.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 78Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | -1.4% |
| 1Y | 10.9% | -16.2% | 11.8% |
Return vs Industry: 78Q exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: 78Q underperformed the German Market which returned 13.9% over the past year.
Price Volatility
| 78Q volatility | |
|---|---|
| 78Q Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 78Q has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 78Q's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 174 | Dario Neri | www.philogen.com |
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase II clinical trial for the treatment of chronic inflammatory disorders; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial.
Philogen S.p.A. Fundamentals Summary
| 78Q fundamental statistics | |
|---|---|
| Market cap | €817.88m |
| Earnings (TTM) | -€29.35m |
| Revenue (TTM) | €3.92m |
208.7x
P/S Ratio-27.9x
P/E RatioIs 78Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 78Q income statement (TTM) | |
|---|---|
| Revenue | €3.92m |
| Cost of Revenue | €18.91m |
| Gross Profit | -€14.99m |
| Other Expenses | €14.36m |
| Earnings | -€29.35m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -0.73 |
| Gross Margin | -382.55% |
| Net Profit Margin | -748.89% |
| Debt/Equity Ratio | 3.2% |
How did 78Q perform over the long term?
See historical performance and comparison